{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:34Z","timestamp":1787027074751,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The increasing cost of cancer medicines is a growing concern for hospitals in the European region, leading to cost reduction strategies, such as price negotiations. The objective of this study is to compare actual prices and discounts of cancer medicines at hospital level across the European region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To report prices and discounts without compromising the hospitals\u2019 anonymity, an anonymization pathway was developed. Pricing data of 15 cancer medicines in 2022 was collected through structured interviews with hospital staff and reference prices were derived from the IQVIA-MIDAS dataset. Descriptive analyses were used to demonstrate product and reference prices. Discounts were aggregated across countries and product types. Furthermore, the accuracy of the participants\u2019 perceptions of their prices compared to others within their country was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>23 hospitals from nine countries participated. To comply with the anonymization pathway, three countries were presented in general terms. The highest prices at hospital level were observed in France, followed by Serbia, Germany, Hungary and the Netherlands. Two Southern and one Northern European country had the lowest prices. When comparing them with their reference prices, Serbia reports the lowest discounts (\u22127%) and the Southern European countries the highest discounts (\u221238%). In addition, at least half of the hospitals had incorrect perceptions of their prices relative to others within their country, with some up to 22% higher than average.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our study is one of few providing discounts and actual prices for 15 cancer medicines, revealing large price variations between and within countries. Additionally, reference prices often fail to provide an accurate indication of the actual price and hospitals have often misguided perceptions on their negotiation performance. Transparent, standardized reporting of prices and coordinated collaborations are essential to strengthen the bargaining power of hospitals and foster informed price negotiations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1736741","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:46:00Z","timestamp":1773038760000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Price transparency of cancer medicines: a crucial step towards informed pricing negotiations in the European region"],"prefix":"10.3389","volume":"17","author":[{"given":"Julie","family":"Vancoppenolle","sequence":"first","affiliation":[{"name":"Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Amsterdam","place":["Amsterdam, Netherlands"]},{"name":"Health Technology and Services Research Department, Technical Medical Centre, University of Twente","place":["Enschede, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Franzen","sequence":"additional","affiliation":[{"name":"Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Amsterdam","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Andrian\u00f2","sequence":"additional","affiliation":[{"name":"Oncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Baltzer","family":"Houlind","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Copenhagen University Hospital \u2013 Amager and Hvidovre","place":["Hvidovre, Denmark"]},{"name":"The Capital Region Pharmacy","place":["Herlev, Denmark"]},{"name":"Department of Drug Design and Pharmacology, University of Copenhagen","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zora","family":"\u0106etkovi\u0107","sequence":"additional","affiliation":[{"name":"University Clinical Center of Serbia","place":["Belgrade, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniek","family":"Dane","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus University Medical Center","place":["Rotterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albane","family":"Degrassat-Th\u00e9as","sequence":"additional","affiliation":[{"name":"Health Law Institute, INSERM UMR S 1145, Paris Cit\u00e9 University","place":["Paris, France"]},{"name":"Faculty of Pharmacy, Paris Cit\u00e9 University","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M. P.","family":"Eldering-Heldens","sequence":"additional","affiliation":[{"name":"Department of Pharmacy","place":["Alkmaar, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Hug","sequence":"additional","affiliation":[{"name":"Medical Center - University of Freiburg","place":["Freiburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Knoth","sequence":"additional","affiliation":[{"name":"Pharmacy Department, University Hospital Carl Gustav Carus, Tecnical University Dresden (TUD)","place":["Dresden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Ladisa","sequence":"additional","affiliation":[{"name":"Departement of Hospital Pharmacy, Fondazione IRCCS Istituto Nazionale dei Tumori","place":["Milano, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Vajda","sequence":"additional","affiliation":[{"name":"University Pharmacy Department of Pharmacy Administration, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Warnke","sequence":"additional","affiliation":[{"name":"Klinikum Ernst von Bergmann GmbH","place":["Potsdam, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valesca","family":"Ret\u00e8l","sequence":"additional","affiliation":[{"name":"Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Amsterdam","place":["Amsterdam, Netherlands"]},{"name":"Erasmus School of Health Policy & Management Health Technology Assessment (HTA)","place":["Rotterdam, Netherlands"]},{"name":"Organization of European Cancer Institutes (OECI)","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim H.","family":"van Harten","sequence":"additional","affiliation":[{"name":"Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Amsterdam","place":["Amsterdam, Netherlands"]},{"name":"Health Technology and Services Research Department, Technical Medical Centre, University of Twente","place":["Enschede, Netherlands"]},{"name":"Organization of European Cancer Institutes (OECI)","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1108\/s0731-2199(2010)0000022006","article-title":"Pharmaceutical policy in the Netherlands: from price regulation towards managed competition","volume":"22","author":"Boonen","year":"2010","journal-title":"Adv. Health Econ. Health Serv. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"q511","DOI":"10.1136\/bmj.q511","article-title":"High cost oncology drugs without proof of added benefit are burdening health systems","volume":"384","author":"Brinkhuis","year":"2024","journal-title":"BMJ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1186\/s12913-022-08866-7","article-title":"Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades","volume":"22","author":"B\u00fcssgen","year":"2022","journal-title":"BMC Health Serv. Res."},{"key":"B4","article-title":"Challenges in access to oncology medicines","author":"Chapman","year":"2020"},{"key":"B26","article-title":"Comit\u00e9 \u00e9conomique des produits de sant\u00e9: rapport d\u2019activit\u00e9 2022","year":"2022"},{"key":"B5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.healthpol.2014.02.011","article-title":"Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices","volume":"116","author":"Curto","year":"2014","journal-title":"Health Policy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jval.2019.12.008","article-title":"Managed entry agreements: policy analysis from the european perspective","volume":"23","author":"Dabbous","year":"2020","journal-title":"Value Health"},{"key":"B7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40258-023-00832-6","article-title":"Prices of orphan drugs in four Western European countries before and after market exclusivity expiry: a cross-country comparison of list prices and purchase prices","volume":"21","author":"Dane","year":"","journal-title":"Appl. Health Econ. Health Policy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1264951","DOI":"10.3389\/fphar.2023.1264951","article-title":"Combatting the rising costs of cancer drugs; interventions from a university hospital's perspective","volume":"14","author":"Dane","year":"","journal-title":"Front. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1016\/S1470-2045(16)00176-5","article-title":"The difficulty of comparing drug prices between countries","volume":"17","author":"De Block","year":"2016","journal-title":"Lancet Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2767-9764.CRC-21-0031","article-title":"Affordable prices without threatening the oncological R&D Pipeline-An economic experiment on transparency in price negotiations","volume":"2","author":"Franzen","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s41669-020-00253-4","article-title":"High-expenditure disease in the EU-28: does drug spend correspond to clinical and economic burden in oncology, autoimmune disease and diabetes?","volume":"5","author":"Greiner","year":"2021","journal-title":"Pharmacoecon Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.jval.2025.06.010","article-title":"Referencing drug prices of other countries may not sustainably lower prices in the United States: lessons from Europe","volume":"28","author":"Grueger","year":"2025","journal-title":"Value Health"},{"key":"B14","article-title":"Access to high-priced medicines in hospital settings in Europe: a study in four European countries health Action international","author":"Hawlik","year":"2014"},{"key":"B15","unstructured":"Delivering most-favored-nation prescription drug pricing to American patients\n          \n          \n            \n              House\n              T. W.\n            \n          \n          \n          2025"},{"key":"B16","article-title":"Global oncology trends 2021: outlook on 2030","year":"2021"},{"key":"B17","unstructured":"All rights reserved\n          \n          \n          2022"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e046917","DOI":"10.1136\/bmjopen-2020-046917","article-title":"Determinants of drug prices: a systematic review of comparison studies","volume":"11","author":"Janssen Daalen","year":"2021","journal-title":"BMJ Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"104681","DOI":"10.1016\/j.healthpol.2022.11.002","article-title":"Evidence on the effectiveness of policies promoting price transparency - a systematic review","volume":"134","author":"Joosse","year":"2023","journal-title":"Health Policy"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1016\/j.drudis.2022.03.018","article-title":"Four scenarios for the future of medicines and social policy in 2030","volume":"27","author":"Leufkens","year":"2022","journal-title":"Drug Discov. Today"},{"key":"B21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40273-023-01320-4","article-title":"Launch and post-launch prices of injectable cancer drugs in the US: clinical benefit, innovation, epidemiology, and competition","volume":"42","author":"Michaeli","year":"2024","journal-title":"Pharmacoeconomics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40258-021-00670-4","article-title":"Comparison of prices and affordability of cancer medicines in 16 countries in Europe and Latin America","volume":"20","author":"Moye-Holz","year":"2022","journal-title":"Appl. Health Econ. Health Policy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s41669-023-00467-2","article-title":"From indication-based pricing to blended approach: evidence on the price and reimbursement negotiation in Italy","volume":"8","author":"Rossini","year":"2024","journal-title":"Pharmacoecon Open"},{"key":"B25","doi-asserted-by":"publisher","first-page":"113042","DOI":"10.1016\/j.socscimed.2020.113042","article-title":"Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US","volume":"258","author":"Salas-Vega","year":"2020","journal-title":"Soc. Sci. and Med."},{"key":"B27","article-title":"Versterken inkoop geneesmiddelen: onderzoek in opdracht van de Nederlandse Vereniging van Ziekenhuizen","year":"2016"},{"key":"B28","article-title":"Prognose uitgaven add-on geneesmiddelen 2022-2026","year":"2022"},{"key":"B29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11523-023-00958-6","article-title":"A systematic evaluation of cost-saving dosing regimens for therapeutic antibodies and antibody-drug conjugates for the treatment of lung cancer","volume":"18","author":"Ter Heine","year":"2023","journal-title":"Target Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S1470-2045(15)00486-6","article-title":"Actual costs of cancer drugs in 15 European countries","volume":"17","author":"Van Harten","year":"2016","journal-title":"Lancet Oncol."},{"key":"B31","first-page":"38","article-title":"Discounts and rebates granted to public payers for medicines in European countries","volume":"5","author":"Vogler","year":"2012","journal-title":"South Med. Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1470-2045(15)00449-0","article-title":"Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study","volume":"17","author":"Vogler","year":"2016","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1736741\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:46:03Z","timestamp":1773038763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1736741\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":30,"alternative-id":["10.3389\/fphar.2026.1736741"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1736741","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"article-number":"1736741"}}